Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.
COVID-19
COVID-19 convalescent plasma
SARS-CoV2
neutralizing antibodies
pathogen-reduction treatment
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
31
07
2022
received:
11
04
2022
accepted:
31
07
2022
pubmed:
3
9
2022
medline:
13
10
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
Efficacy of donated COVID-19 convalescent plasma (dCCP) is uncertain and may depend on antibody titers, neutralizing capacity, timing of administration, and patient characteristics. In a single-center hypothesis-generating prospective case-control study with 1:2 matched dCCP recipients to controls according to disease severity at day 1, hospitalized adults with COVID-19 pneumonia received 2 × 200 ml pathogen-reduced treated dCCP from 2 different donors. We evaluated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in COVID-19 convalescent plasma donors and recipients using multiple antibody assays including a Coronavirus antigen microarray (COVAM), and binding and neutralizing antibody assays. Outcomes were dCCP characteristics, antibody responses, 28-day mortality, and dCCP -related adverse events in recipients. Eleven of 13 dCCPs (85%) contained neutralizing antibodies (nAb). PRT did not affect dCCP antibody activity. Fifteen CCP recipients and 30 controls (median age 64 and 65 years, respectively) were enrolled. dCCP recipients received 2 dCCPs from 2 different donors after a median of one hospital day and 11 days after symptom onset. One dCCP recipient (6.7%) and 6 controls (20%) died (p = 0.233). We observed no dCCP-related adverse events. Transfusion of unselected dCCP led to heterogeneous SARS CoV-2 antibody responses. COVAM clustered dCCPs in 4 distinct groups and showed endogenous immune responses to SARS-CoV-2 antigens over 14-21 days post dCCP in all except 4 immunosuppressed recipients. PRT did not impact dCCP anti-virus neutralizing activity. Transfusion of unselected dCCP did not impact survival and had no adverse effects. Variable dCCP antibodies and post-transfusion antibody responses indicate the need for controlled trials using well-characterized dCCP with informative assays.
Sections du résumé
BACKGROUND
Efficacy of donated COVID-19 convalescent plasma (dCCP) is uncertain and may depend on antibody titers, neutralizing capacity, timing of administration, and patient characteristics.
STUDY DESIGN AND METHODS
In a single-center hypothesis-generating prospective case-control study with 1:2 matched dCCP recipients to controls according to disease severity at day 1, hospitalized adults with COVID-19 pneumonia received 2 × 200 ml pathogen-reduced treated dCCP from 2 different donors. We evaluated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in COVID-19 convalescent plasma donors and recipients using multiple antibody assays including a Coronavirus antigen microarray (COVAM), and binding and neutralizing antibody assays. Outcomes were dCCP characteristics, antibody responses, 28-day mortality, and dCCP -related adverse events in recipients.
RESULTS
Eleven of 13 dCCPs (85%) contained neutralizing antibodies (nAb). PRT did not affect dCCP antibody activity. Fifteen CCP recipients and 30 controls (median age 64 and 65 years, respectively) were enrolled. dCCP recipients received 2 dCCPs from 2 different donors after a median of one hospital day and 11 days after symptom onset. One dCCP recipient (6.7%) and 6 controls (20%) died (p = 0.233). We observed no dCCP-related adverse events. Transfusion of unselected dCCP led to heterogeneous SARS CoV-2 antibody responses. COVAM clustered dCCPs in 4 distinct groups and showed endogenous immune responses to SARS-CoV-2 antigens over 14-21 days post dCCP in all except 4 immunosuppressed recipients.
DISCUSSION
PRT did not impact dCCP anti-virus neutralizing activity. Transfusion of unselected dCCP did not impact survival and had no adverse effects. Variable dCCP antibodies and post-transfusion antibody responses indicate the need for controlled trials using well-characterized dCCP with informative assays.
Identifiants
pubmed: 36054476
doi: 10.1111/trf.17083
pmc: PMC9538076
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1997-2011Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR001416
Pays : United States
Informations de copyright
© 2022 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Références
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
JAMA. 2021 Aug 17;326(7):589-590
pubmed: 34319350
N Engl J Med. 2022 May 5;386(18):1700-1711
pubmed: 35353960
J Vis Exp. 2019 Jul 26;(149):
pubmed: 31403629
N Engl J Med. 2022 Feb 10;386(6):509-520
pubmed: 34914868
J Infect Dis. 2020 Jun 16;222(1):38-43
pubmed: 32348485
N Engl J Med. 2021 Mar 4;384(9):795-807
pubmed: 33306283
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Clin Infect Dis. 2021 Jul 1;73(1):e208-e214
pubmed: 33038227
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):1250-1255
pubmed: 29358368
J Clin Invest. 2021 Oct 15;131(20):
pubmed: 34473652
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32513859
N Engl J Med. 2021 Nov 18;385(21):1951-1960
pubmed: 34407339
Science. 2021 Aug 13;373(6556):
pubmed: 34210892
Blood. 2020 Aug 6;136(6):755-759
pubmed: 32573724
J Clin Invest. 2020 Sep 1;130(9):4791-4797
pubmed: 32525844
Nat Commun. 2021 Jan 4;12(1):6
pubmed: 33397903
Nat Med. 2020 Nov;26(11):1708-1713
pubmed: 32934372
J Med Virol. 2020 Oct;92(10):2042-2049
pubmed: 32369191
Infez Med. 2020 Sep 1;28(3):357-366
pubmed: 32920571
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
JCI Insight. 2021 Feb 22;6(4):
pubmed: 33476300
ACS Cent Sci. 2016 Mar 23;2(3):139-147
pubmed: 27064772
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Nat Commun. 2022 Jan 19;13(1):383
pubmed: 35046397
JAMA. 2021 Mar 23;325(12):1185-1195
pubmed: 33635310
Lancet. 2021 May 29;397(10289):2049-2059
pubmed: 34000257
Transfusion. 2021 Aug;61(8):2503-2511
pubmed: 34036587
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Blood. 2020 Nov 12;136(20):2290-2295
pubmed: 32959052
Swiss Med Wkly. 2021 Aug 10;151:w20550
pubmed: 34375986
JCI Insight. 2021 Mar 22;6(6):
pubmed: 33571168
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
Lancet Respir Med. 2021 Dec;9(12):1349-1351
pubmed: 34480862
Front Med (Lausanne). 2021 Apr 09;8:624924
pubmed: 33898477
Transfus Apher Sci. 2020 Oct;59(5):102875
pubmed: 32694043
Transfusion. 2021 Apr;61(4):1160-1170
pubmed: 33554362
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
J Med Virol. 2021 Apr;93(4):2374-2384
pubmed: 33314153
J Med Virol. 2022 Apr;94(4):1627-1632
pubmed: 34888894
Vox Sang. 2021 Jul;116(6):673-681
pubmed: 33277935
J Med Virol. 2021 Apr;93(4):2160-2167
pubmed: 33064340
J Korean Med Sci. 2020 Apr 13;35(14):e149
pubmed: 32281317
Transfusion. 2022 Mar;62(3):570-583
pubmed: 35128658
Int J Infect Dis. 2021 Feb;103:439-446
pubmed: 33285283
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Nat Commun. 2021 Aug 11;12(1):4864
pubmed: 34381030
Nat Med. 2021 Nov;27(11):2012-2024
pubmed: 34504336
SLAS Technol. 2020 Dec;25(6):545-552
pubmed: 32815769
J Med Virol. 2020 Oct;92(10):1890-1901
pubmed: 32293713
Indian J Hematol Blood Transfus. 2021 Jul;37(3):347-365
pubmed: 33746378
Am J Pathol. 2020 Aug;190(8):1680-1690
pubmed: 32473109
Vox Sang. 2021 Sep;116(8):930-931
pubmed: 33745163
J Infect Dis. 2020 Sep 14;222(8):1270-1279
pubmed: 32726441
Transfusion. 2022 Oct;62(10):1997-2011
pubmed: 36054476
BMJ. 2020 Oct 22;371:m3939
pubmed: 33093056
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
J Clin Microbiol. 2021 Nov 18;59(12):e0138121
pubmed: 34524886
Sci Rep. 2021 May 11;11(1):9927
pubmed: 33976287
Lancet Rheumatol. 2020 Oct;2(10):e589-e590
pubmed: 33521659
Mayo Clin Proc. 2021 May;96(5):1262-1275
pubmed: 33958057
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
N Engl J Med. 2021 Feb 18;384(7):619-629
pubmed: 33232588
Nat Commun. 2021 May 27;12(1):3189
pubmed: 34045486
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Transfus Med Rev. 2020 Jul;34(3):141-144
pubmed: 32359789
J Med Virol. 2021 Mar;93(3):1678-1686
pubmed: 32965715
mSphere. 2018 Dec 12;3(6):
pubmed: 30541779
Proteomics. 2016 Apr;16(8):1271-9
pubmed: 26842269
Trials. 2021 May 4;22(1):323
pubmed: 33947446
Surgery. 1962 Feb;51(2):224-32
pubmed: 21936146
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353
Transfus Med. 2005 Aug;15(4):269-76
pubmed: 16101804
JAMA. 2020 Apr 28;323(16):1561-1562
pubmed: 32219429